ASNDAscendis Pharma A/S

$250.34

$189.7452 weeks$270.80

Price

$250.34+32%1Y

1M-0.84%1Y+32%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

8/10

Value31

Quality85

Momentum68

Growth93

Strongest Growth, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we develop TransCon-based therapies that demonstrate best-in-class potential to address unmet medical needs. Our portfolio of Endocrinology Rare Disease approved products and product candidates addresses hypoparathyroidism and growth disorders.

In the company’s own words · 20-F filed Feb 11, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$15.14B

1Y Return+32%

5Y Return+108%

Ascendis Pharma A/S (ASND) reported revenue of €248M in Q4 2025 (quarter ended December 31, 2025), up 42% from the same quarter a year earlier. That came with a gross margin of 90% and net loss of €34M. For the full year FY2025, revenue was €720M (+98% year on year) and net income −€228M.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #59 of 145 by Smart Score

Jazz Pharmaceuticals plc

BBIO+0.48%

BridgeBio Pharma, Inc.